Jaguar Health, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -52.15 | — | — |
| 2025-11-14 | -177.80 | -219.80 | -23.62% |
| 2025-08-14 | -249.55 | -259.26 | -3.89% |
| 2025-05-15 | -378.70 | -584.50 | -54.34% |
| 2025-03-31 | -647.50 | -4403.00 | -580.00% |
| 2024-11-13 | -2073.75 | -918.75 | +55.70% |
| 2024-08-13 | -1050.00 | -3535.00 | -236.67% |
| 2024-05-14 | -1575.00 | -3459.75 | -119.67% |
| 2023-11-14 | -64574.94 | -19949.98 | +69.11% |
| 2023-08-14 | -80324.92 | -36224.96 | +54.90% |
| 2023-05-15 | -236250.35 | -125474.87 | +46.89% |
| 2022-11-14 | -275625.41 | -472500.71 | -71.43% |
| 2022-08-22 | -748126.12 | -472500.71 | +36.84% |
| 2022-05-10 | -708751.06 | -1335995.75 | -88.50% |
| 2022-03-11 | -315000.47 | -1220626.83 | -287.50% |
| 2021-11-17 | -787501.18 | -1063126.59 | -35.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| JAGX | -46.94% | -83.51% | -89.11% | -97.69% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -49.90% | -78.87% | -85.66% | -110.38% |